RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

European Commission approves Roche ’s tocilizumab to treat giant cell arteritis
Roche ’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval for Gazyvaro, European approval for Actemra
ZURICH (Reuters) - Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Media News)
Source: Roche Media News - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news